TY - JOUR

T1 - FRAX calculated without BMD resulting in a higher fracture risk than that calculated with BMD in women with early breast cancer

AU - Prawiradilaga, Rizky Suganda

AU - Gunmalm, Victoria

AU - Lund-Jacobsen, Trine

AU - Helge, Eva Wulff

AU - Brøns, Charlotte

AU - Andersson, Michael

AU - Schwarz, Peter

N1 - CURIS 2018 NEXS 390

PY - 2018

Y1 - 2018

N2 - Background (and Purpose): The aim of this study was to investigate the importance of including the measurement of bone mineral density (BMD) in reliable fracture risk assessment for women diagnosed with early nonmetastatic breast cancer (EBC) before AI treatment if zoledronic acid is not an option. Material and Methods: One hundred and sixteen women with EBC were includedin the study before initiating AI treatment. Most participants were osteopenic. The 10-year probability of hip fracture and major osteoporotic fracture was calculated with and without BMD based on clinical information collected at baseline using the fracture risk assessment (FRAX) tool. To compare data, the nonparametric tests were used. Results: There was a signifcant diference (p<0.001) in the number of high-risk and low-risk FRAX score of hip fracture between before and after including BMD values. The high-risk category decreased by 50.9%, while the low-risk category increased by 42.9%. In FRAX score of major osteoporotic the findings were similar (p<0.001): The high-risk and moderate-risk category decreased by 70.4% and 4.9%, respectively, while the low-risk category increased by 43.8% when including BMD value. When stratifed by age, patients aged 65 years or older were at asignifcantly (p<0.001) higher risk of suffering a hip or major osteoporotic fracture, highlighting the importance of including BMD measurements in this age group. Conclusions: Our data support that DXA scanning of women with EBC should be performed to avoid overestimation of osteoporosis before AI treatment. It is particularly important in patients older than 65 years of age and when zoledronic acid is not an option.

AB - Background (and Purpose): The aim of this study was to investigate the importance of including the measurement of bone mineral density (BMD) in reliable fracture risk assessment for women diagnosed with early nonmetastatic breast cancer (EBC) before AI treatment if zoledronic acid is not an option. Material and Methods: One hundred and sixteen women with EBC were includedin the study before initiating AI treatment. Most participants were osteopenic. The 10-year probability of hip fracture and major osteoporotic fracture was calculated with and without BMD based on clinical information collected at baseline using the fracture risk assessment (FRAX) tool. To compare data, the nonparametric tests were used. Results: There was a signifcant diference (p<0.001) in the number of high-risk and low-risk FRAX score of hip fracture between before and after including BMD values. The high-risk category decreased by 50.9%, while the low-risk category increased by 42.9%. In FRAX score of major osteoporotic the findings were similar (p<0.001): The high-risk and moderate-risk category decreased by 70.4% and 4.9%, respectively, while the low-risk category increased by 43.8% when including BMD value. When stratifed by age, patients aged 65 years or older were at asignifcantly (p<0.001) higher risk of suffering a hip or major osteoporotic fracture, highlighting the importance of including BMD measurements in this age group. Conclusions: Our data support that DXA scanning of women with EBC should be performed to avoid overestimation of osteoporosis before AI treatment. It is particularly important in patients older than 65 years of age and when zoledronic acid is not an option.

U2 - 10.1155/2018/4636028

DO - 10.1155/2018/4636028

M3 - Journal article

C2 - 30631415

VL - 2018

JO - Journal of Osteoporosis

JF - Journal of Osteoporosis

SN - 2090-8059

M1 - 4636028

ER -